Fifth PD-1, Zavicefta, Novel Psoriasis Ointment Among Latest China Approvals

 
• By Brian Yang

Jiangsu Hengrui’s anti-PD-1 antibody is the latest to hit the immuno-oncology market in China, ensuring a fierce battle in pricing and reimbursement. Other recent new approvals include Pfizer’s antibacterial Zavicefta and a first-in-class topical treatment for psoriasis.

Psoriatic Skin_1200x675
GLOBAL FIRST APPROVAL IN CHINA FOR NOVEL PSORIASIS AGENT • Source: Shutterstock

More from China

More from Asia